{"id":985649,"date":"2026-07-28T09:19:13","date_gmt":"2026-07-28T13:19:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/"},"modified":"2026-07-28T09:19:13","modified_gmt":"2026-07-28T13:19:13","slug":"exagen-inc-to-participate-in-upcoming-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/","title":{"rendered":"Exagen Inc. to Participate in Upcoming Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CARLSBAD, Calif., July  28, 2026  (GLOBE NEWSWIRE) &#8212; Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference:<\/p>\n<p>\n        <strong>Canaccord Genuity 46<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Growth Conference \u2013 Boston, MA<br \/><\/strong>Date: August 11, 2026<br \/>Fireside Chat at 8:30am ET<br \/>A live and archived webcast of the Fireside Chat will be available on Exagen\u2019s Investor Relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eWy486OvBz3nGXOX0PgeMNgHnjSIKRIvrklcalCcJBYc2SIfV6BQn22qjGkNjzCyOb4FfTKBrVkqpuLXhJKtY-HrNDyPAPvz0tsWDuBm4f8=\" rel=\"nofollow\" target=\"_blank\">investors.exagen.com<\/a>.<\/p>\n<p>\n        <strong>About Exagen Inc.<br \/><\/strong>Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen\u2019s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company\u2019s flagship product, AVISE\u00ae CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sj\u00f6gren\u2019s disease earlier and with greater accuracy. Exagen\u2019s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NLDnXYiT7hjfL2FimN8hWGOcBPK8-mn_HeltDJQ_q_j53KLdflIp5zfQmWJ8dT4dVJHnCKBQstNhw50ldQ7Eqw==\" rel=\"nofollow\" target=\"_blank\">Exagen.com<\/a> or follow Exagen on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LHgRsi6NSfeHdnWbomFeNQU6E1uaE0Y_fcnAFlkh6zZB6CDfBrPYFRb5bNMXllcWUGW7I4uCrJ4A7lp3_P-jl3TuUykTqQ_TTWxOFw1tc_LCMUKKSUo3vTujSRi-i1DA8_8ZsXWjD0IJhxRkapZybQ==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Tina Jacobsen, CFA<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hZCcTFzbcqvqVH0iiNUit_xVereXo_PbA5ELrkzx76HBvEJB0rbKYmKAvdUigf7GkzygFByNuoHi4AFRk3DSFA==\" rel=\"nofollow\" target=\"_blank\">IR@exagen.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODc2NyM3NzQ1MTgzIzIwMTA5NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2IyODZmNjMtYmNhNi00MjljLTgxNTQtNzRjZWEwOTVmYzdiLTEwMjI1NDUtMjAyNi0wNy0yOC1lbg==\/tiny\/Exagen-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) &#8212; Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord Genuity 46 th Annual Growth Conference \u2013 Boston, MADate: August 11, 2026Fireside Chat at 8:30am ETA live and archived webcast of the Fireside Chat will be available on Exagen\u2019s Investor Relations website at investors.exagen.com. About Exagen Inc.Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen\u2019s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company\u2019s flagship product, AVISE\u00ae CTD, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Exagen Inc. to Participate in Upcoming Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-985649","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exagen Inc. to Participate in Upcoming Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exagen Inc. to Participate in Upcoming Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) &#8212; Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord Genuity 46 th Annual Growth Conference \u2013 Boston, MADate: August 11, 2026Fireside Chat at 8:30am ETA live and archived webcast of the Fireside Chat will be available on Exagen\u2019s Investor Relations website at investors.exagen.com. About Exagen Inc.Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen\u2019s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company\u2019s flagship product, AVISE\u00ae CTD, &hellip; Continue reading &quot;Exagen Inc. to Participate in Upcoming Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T13:19:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODc2NyM3NzQ1MTgzIzIwMTA5NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-to-participate-in-upcoming-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-to-participate-in-upcoming-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exagen Inc. to Participate in Upcoming Investor Conference\",\"datePublished\":\"2026-07-28T13:19:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-to-participate-in-upcoming-investor-conference\\\/\"},\"wordCount\":224,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-to-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5ODc2NyM3NzQ1MTgzIzIwMTA5NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-to-participate-in-upcoming-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-to-participate-in-upcoming-investor-conference\\\/\",\"name\":\"Exagen Inc. to Participate in Upcoming Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-to-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-to-participate-in-upcoming-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5ODc2NyM3NzQ1MTgzIzIwMTA5NzI=\",\"datePublished\":\"2026-07-28T13:19:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-to-participate-in-upcoming-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-to-participate-in-upcoming-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-to-participate-in-upcoming-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5ODc2NyM3NzQ1MTgzIzIwMTA5NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5ODc2NyM3NzQ1MTgzIzIwMTA5NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-to-participate-in-upcoming-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exagen Inc. to Participate in Upcoming Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exagen Inc. to Participate in Upcoming Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Exagen Inc. to Participate in Upcoming Investor Conference - Market Newsdesk","og_description":"CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) &#8212; Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord Genuity 46 th Annual Growth Conference \u2013 Boston, MADate: August 11, 2026Fireside Chat at 8:30am ETA live and archived webcast of the Fireside Chat will be available on Exagen\u2019s Investor Relations website at investors.exagen.com. About Exagen Inc.Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen\u2019s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company\u2019s flagship product, AVISE\u00ae CTD, &hellip; Continue reading \"Exagen Inc. to Participate in Upcoming Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-28T13:19:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODc2NyM3NzQ1MTgzIzIwMTA5NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exagen Inc. to Participate in Upcoming Investor Conference","datePublished":"2026-07-28T13:19:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/"},"wordCount":224,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODc2NyM3NzQ1MTgzIzIwMTA5NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/","name":"Exagen Inc. to Participate in Upcoming Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODc2NyM3NzQ1MTgzIzIwMTA5NzI=","datePublished":"2026-07-28T13:19:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODc2NyM3NzQ1MTgzIzIwMTA5NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODc2NyM3NzQ1MTgzIzIwMTA5NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-to-participate-in-upcoming-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exagen Inc. to Participate in Upcoming Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/985649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=985649"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/985649\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=985649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=985649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=985649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}